2 completed, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Enoblituzumab: new trials by email Literature Review of Enoblituzumab trials Research Report on Enoblituzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer FT538, Enoblituzumab - Cancer, Solid Tumor | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2023-04-28 | 2025-08-14 |
| FT516 and IL2 With Enoblituzumab for Ovarian Cancer IP FT516, Enoblituzumab, IL-2 - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 3 | 2021-04-02 | 2023-04-03 |
| Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Enoblituzumab - Neuroblastoma, Rhabdomyosarcoma | Phase 1 | Completed | MacroGenics | 25 | 2016-12-01 | 2022-02-08 |
Ovarian Neoplasms (2) · Desmoplastic Small Round Cell Tumor (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Neuroblastoma (1) · Osteosarcoma (1) · Rhabdomyosarcoma (1) · Sarcoma, Ewing (1) · Wilms Tumor (1)
Masonic Cancer Center, University of Minnesota (2) · MacroGenics (1)
United States (3)
P01CA111412 (2)